Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -37.87% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 107.90M USD | Price to earnings Ratio - | 1Y Target Price 15.56 |
Price to earnings Ratio - | 1Y Target Price 15.56 | ||
Volume (30-day avg) 1146533 | Beta 3 | 52 Weeks Range 1.39 - 8.08 | Updated Date 04/2/2025 |
52 Weeks Range 1.39 - 8.08 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -295.96% | Operating Margin (TTM) -728.4% |
Management Effectiveness
Return on Assets (TTM) -20.17% | Return on Equity (TTM) -45.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77277837 | Price to Sales(TTM) 3.03 |
Enterprise Value -77277837 | Price to Sales(TTM) 3.03 | ||
Enterprise Value to Revenue 8.85 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 70989696 | Shares Floating 47248589 |
Shares Outstanding 70989696 | Shares Floating 47248589 | ||
Percent Insiders 11.51 | Percent Institutions 91.5 |
Analyst Ratings
Rating 4.22 | Target Price 16.38 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics, Inc. (founded in 2011) is a biopharmaceutical company focused on developing targeted protein degradation therapeutics to treat cancer and other diseases. It leverages its TORPEDO platform to discover and design small-molecule drugs that selectively degrade disease-causing proteins.
Core Business Areas
- Oncology: Developing targeted protein degradation therapies for various cancer types.
- Other Diseases: Exploring applications of targeted protein degradation beyond oncology.
- Drug Discovery Platform: Utilizing the TORPEDO platform for drug discovery and development.
Leadership and Structure
Andrew Hirsch (President and CEO); the company has a typical biotech structure with research, development, and corporate functions.
Top Products and Market Share
Key Offerings
- CFT7455: An investigational degrader targeting IKZF1/3 for multiple myeloma and lymphoma. Phase 1/2 clinical trials are ongoing. No current market share available. Competitors include companies developing similar protein degraders such as Arvinas, Kymera Therapeutics, and Nurix Therapeutics.
- CFT8634: An investigational degrader targeting BRD9 for synovial sarcoma and other solid tumors. Phase 1/2 clinical trials are ongoing. No current market share available. Competitors include companies developing similar protein degraders such as Arvinas, Kymera Therapeutics, and Nurix Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Targeted protein degradation is an emerging field with significant potential.
Positioning
C4 Therapeutics is a leader in the targeted protein degradation space, with a proprietary platform and a pipeline of clinical-stage programs. Its competitive advantage lies in its TORPEDO platform.
Total Addressable Market (TAM)
The TAM for targeted protein degradation therapeutics is estimated to be in the billions of dollars, addressing a wide range of diseases. C4 Therapeutics is positioned to capture a portion of this market with its pipeline and platform.
Upturn SWOT Analysis
Strengths
- Proprietary TORPEDO platform
- Clinical-stage pipeline
- Strong scientific team
- Strategic collaborations
Weaknesses
- Dependence on clinical trial success
- Limited revenue
- High cash burn rate
- Competition in the protein degradation field
Opportunities
- Expanding pipeline into new disease areas
- Partnering with larger pharmaceutical companies
- Advancing clinical programs to commercialization
- Improving drug delivery
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ARVN
- KYMR
- NRIX
Competitive Landscape
C4 Therapeutics competes with other biopharmaceutical companies developing targeted protein degradation therapies. Its TORPEDO platform and clinical pipeline are key differentiators.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by pipeline advancement and strategic collaborations.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing clinical programs, expanding the pipeline, and securing partnerships.
Summary
C4 Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation. The company's TORPEDO platform holds promise, but it's reliant on clinical trial outcomes. It's competing in a space against bigger firms, needing success in clinical programs and collaborations to thrive. Financial performance will depend on future approvals and commercialization.
Similar Companies
ARVN
Arvinas Inc
ARVN
Arvinas Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
KYMR
Kymera Therapeutics Inc
KYMR
Kymera Therapeutics Inc
NRIX
Nurix Therapeutics Inc
NRIX
Nurix Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, press releases, analyst reports.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant to treat melanoma, colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC under preclinical stage. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA, Darmstadt, Germany; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.